Study raises hopes for 'female Viagra'

Arousal in women experiencing sexual dysfunction could be restored by an experimental drug, researchers have claimed.

Such therapies, dubbed ‘female Viagra' by the media, may help treat female sexual arousal disorder (FSAD), claimed to affect up to 40% of women.

In a series of experiment on rabbits, researchers from Pfizer showed that genital blood flow was increased by the experimental drug UK-414, 495, a neutral endopeptidase. Reductions in genital blood circulation have been proposed as a cause of FSAD.

Writing in the British Journal of Pharmacology the researchers concluded that neutral endopeptidases ‘may restore sexual arousal in women adversely affected by FSAD'.

Lead researcher Chris Wayman commented: ‘While the particular chemical compound studied in this research did not prove appropriate for further development, the implications of the research could lead to the development of a product in future, although Pfizer has no current plans to develop medicines for FSAD'.

Tom Moberly recommends

MIMS drug information - Viagra

Read more

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus